Clinical trials: open to volunteers, in Denmark
Advanced Solid Tumors
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to investigate the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
- Trial name
- NCT06697197
- Testing
- BMS-986482, Pumitamig
- Where
- 21 sites in United States, Belgium and 7 more
- Volunteers
- 286 people
- Sponsor
- Bristol-Myers Squibb
Diffuse Large B-Cell Lymphoma
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
- Trial name
- NCT06717347
- Testing
- Zilovertamab vedotin, Rituximab, Cyclophosphamide
- Where
- 285 sites in United States, Argentina and 33 more
- Volunteers
- 1,046 people
- Sponsor
- Merck Sharp & Dohme LLC
Colon Cancer, Frailty
Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)
The purpose of the study is to investigate whether an extended program (ERAS 3.0) initiated hospital discharge, can improve recovery in elderly, frail patients who have undergone surgery for colon cancer.
- Trial name
- NCT06802991
- Testing
- ERAS 3.0 (Enhanced Recovery After Surgery)
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital at Herlev
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the…
- Trial name
- CLEOPATTRA (NCT07207811)
- Testing
- NNC6019-0001
- Where
- 299 sites in United States, Argentina and 18 more
- Volunteers
- 1,280 people
- Sponsor
- Novo Nordisk A/S
Von Hippel-Lindau Disease, Malignant Neoplasms
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery Solid…
- Trial name
- NCT07405164
- Testing
- Belzutifan, Nivolumab, Lenvatinib
- Where
- 57 sites in United States, Australia and 20 more
- Volunteers
- 450 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy.
- Trial name
- NCT07489495
- Testing
- Belzutifan, Zanzalintinib
- Where
- 103 sites in United States, Argentina and 17 more
- Volunteers
- 758 people
- Sponsor
- Merck Sharp & Dohme LLC
High-Risk Neuroblastoma
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years.
- Trial name
- SHINE (NCT07549321)
- Testing
- hu1418K322A + Temozolomide + Irinotecan
- Where
- 17 sites in United States, Canada and 5 more
- Volunteers
- 144 people
- Sponsor
- Renaissance Pharma Ltd.
Malignant Neoplasm
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Researchers are looking for new ways to treat children with relapsed or refractory solid tumors: Relapsed means the cancer came back after treatment Refractory means the cancer did not respond (get smaller or go away) to…
- Trial name
- NCT07630974
- Testing
- Ifinatamab Deruxtecan
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 134 people
- Sponsor
- Merck Sharp & Dohme LLC
Newly Diagnosed Multiple Myeloma (NDMM)
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
The purpose of this study is to measure the efficacy of AZD0120 compared with ASCT in terms of progression-free survival (PFS) according to the International Myeloma Working Group (IMWG) criteria 2016, and MRD negative complete…
- Trial name
- DURGA-6 (NCT07735637)
- Testing
- AZD0120, Cyclophosphamide, Fludarabine
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Heart Transplantation
Donor Derived Cell Free DNA (Dd-cfDNA) as a Biomarker for Allograft Rejection in Heart Transplant Recipients
Following heart transplantation (HTx), lifelong immunosuppressive treatment is required to prevent the immune system from attacking, damaging, and rejecting the donor hear (allograft).
- Trial name
- TRANSCEND (NCT07886489)
- Testing
- Donor-derived cell free DNA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Cardiac Rhythm Disorders, Urological Disorders
Product Surveillance Registry
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products.
- Conditions
- Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
- Trial name
- PSR (NCT01524276)
- Where
- 402 sites in United States, Argentina and 39 more
- Volunteers
- 100,000 people
- Sponsor
- Medtronic
Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab…
- Trial name
- CAMMA 1 (NCT04910568)
- Testing
- Cevostamab, Tocilizumab, Pomalidomide
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 186 people
- Sponsor
- Genentech, Inc.
Type 1 Diabetes Mellitus With Diabetic Nephropathy
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
The aim of this study is to test the hypothesis that dapagliflozin (SGLT2 inhibitor) and SC0062 (ERA) combination therapy augments nephroprotection and mitigates fluid retention and ketogenesis in people with T1D through…
- Trial name
- ASPIRE-1 (NCT06072326)
- Testing
- Dapagliflozin (Forxiga®), SC0062 strength 10mg, SC0062 and dapagliflozin
- Where
- 5 sites in Denmark, Finland
- Volunteers
- 36 people
- Sponsor
- University Medical Center Groningen
Advanced Solid Tumor
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in…
- Trial name
- NCT06589596
- Testing
- BGB-58067, BG-89894, Standard of Care Therapy
- Where
- 101 sites in United States, Australia and 9 more
- Volunteers
- 695 people
- Sponsor
- BeOne Medicines
Advanced Solid Tumors Harboring KRAS G12C Mutation
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
Researchers are looking for a better way to treat people who have advanced solid cancers with a KRASG12C mutation. Sotorasib is a drug that targets cancer cells which contain mutated KRASG12C protein; it can stop the cancer cells…
- Trial name
- NCT06659341
- Testing
- BAY3498264
- Where
- 11 sites in Australia, Denmark and 3 more
- Volunteers
- 104 people
- Sponsor
- Bayer
Transthyretin Amyloidosis With Cardiomyopathy
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
The purpose of this study is to: Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events Evaluate the efficacy of nucresiran compared to placebo on additional…
- Trial name
- NCT07052903
- Testing
- Nucresiran, Sterile Normal Saline (0.9% NaCl)
- Where
- 266 sites in United States, Argentina and 34 more
- Volunteers
- 1,750 people
- Sponsor
- Alnylam Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups.
- Trial name
- AEOLUS (NCT07053423)
- Testing
- Dupilumab
- Where
- 85 sites in United States, Argentina and 20 more
- Volunteers
- 218 people
- Sponsor
- Sanofi
Autoimmune Haemolytic Anaemia
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female…
- Trial name
- LUMINA 3 (NCT07086976)
- Testing
- rilzabrutinib
- Where
- 105 sites in United States, Argentina and 16 more
- Volunteers
- 90 people
- Sponsor
- Sanofi
Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Current therapeutic strategies for high-risk or relapsed ALL patients often involve intensive treatments, including allogeneic hematopoietic stem cell transplantation (HSCT).
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-disease
- Trial name
- FORUM2 (NCT07297914)
- Testing
- Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab
- Where
- 9 sites in Austria, Czechia and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Immune-Related Adverse Events
Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events
The goal of this clinical trial is to investigate the safety of rituximab for management of immune-related adverse events in malignant melanoma patients.
- Trial name
- RiTOX (NCT07694414)
- Testing
- Rituximab (RTX)
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Inge Marie Svane